CODX

• 

  Co-Diagnostics, Inc. Announces Participation in Research Project with Stanford University

  12:33 PM|June 1, 2018

  CoPrimers™ used in proof of concept evaluation SALT LAKE CITY–(BUSINESS WIRE)– Co-Diagnostics, Inc. (NASDAQ: CODX), a diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced today that the Company’s CoPrimer™ technology is being employed to achieve the objectives of a research project conducted by the Wang Group at Stanford University. The purpose of the study is to develop more efficient methods to detect multiple genetic mutations in the EGFR (epidermal growth factor receptor) gene, including the

  Read more
• 

  Co-Diagnostics Files Initial Annual Report on Form 10-K and Updates Corporate Developments

  9:44 AM|April 5, 2018

  CODX updates on initial six months as a public company SALT LAKE CITY–(BUSINESS WIRE)– Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced the filing of its initial Annual Report on Form 10-K as a public company. Co-Diagnostics completed its initial public offering (“IPO”) on July 17, 2017. 2017 Financial Results: Revenue for the year totaled $7,700, primarily licensing revenue, compared to zero revenue in full year 2016. Deferred income

  Read more
• 

  Co-Diagnostics, Inc. Announces Construction Update at JV Manufacturing Facility in India

  10:42 AM|March 22, 2018

  Project moving forward on schedule, with production to begin in Q3 2018 SALT LAKE CITY–(BUSINESS WIRE)– Co-Diagnostics, Inc. (NASDAQ: CODX), a diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced today an update on the Joint Venture (“JV”) manufacturing facility in Vadodara, India. CoSara Diagnostics, Pvt., Ltd. (“CoSara”), the JV for manufacturing with Synbiotics Limited, a group company of Asence Inc, a U.S. incorporated company specializing in supplying pharmaceutical products to international markets, broke ground on

  Read more
• 

  Co-Diagnostics Inc Announces Positive Results from Co-Primers™ Technology in Multiplex Tests for SNP Detection

  8:43 AM|February 28, 2018

  SALT LAKE CITY–(BUSINESS WIRE)– Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today that ongoing research and development activities of the Company’s Co-Primer™ platform technology has yielded positive results in demonstrating the capabilities of Co-Primers in multiplex tests for SNP detection. The Company will utilize its proprietary design software and patent-pending Co-Primer technology to provide molecular testing solutions for use by customers. These include enterprise

  Read more
• 

  Co-Diagnostics, Inc. Enters Into Lease for New, Upgraded Laboratory Facility

  11:46 AM|December 20, 2017

  Laboratory will meet CGMP Requirements of FDA; Will be BSL-2 to allow enhanced in-house verification and validation activities SALT LAKE CITY–(BUSINESS WIRE)– Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today leasing a new and upgraded, CGMP-ready and Biological Safety Level 2 laboratory facility in Salt Lake City, Utah. Co-Diagnostics CEO Dwight Egan remarked, “The upgraded facility is nearly perfectly appointed with the necessary amenities to immediately commence production

  Read more
• 

  Co-Diagnostics, Inc. to Present Zika Tests to Dominican Republic Ministry of Health

  9:40 AM|October 16, 2017

  SANDY, Utah–CODX, (BUSINESS WIRE)– Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today upcoming meetings with the Ministry of Public Health and Social Assistance (SESPAS) of the Dominican Republic to discuss the Company’s products. The meetings will take place the week of October 16, 2017, with senior officials of the Centro Nacional de Control de Enfermedades Tropicales (National Center of Control of Tropical Diseases,

  Read more